Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screeningMENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: ...
Is nearing full enrollment for its NEO100-01 Phase 2a trial, with top-line data readout anticipated in early 2026. The final patient cohort in its NEO212 Phase I trial is also on track for completion ...
PW Consulting has released a comprehensive research report in 2025 that delves deeply into the Hollow Silica Nanoparticle Mar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback